Long-term antibody production and viremia in American mink (Neovison vison) challenged with Aleutian mink disease virus.
Aleutian mink disease virus
American mink
Antibody production
Tolerance
Viremia
Virus clearance
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
03 Oct 2022
03 Oct 2022
Historique:
received:
21
10
2021
accepted:
16
09
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
6
10
2022
Statut:
epublish
Résumé
Selecting American mink (Neovison vison) for tolerance to Aleutian mink disease virus (AMDV) has gained popularity in recent years, but data on the outcomes of this activity are scant. The objectives of this study were to determine the long-term changes in viremia, seroconversion and survival in infected mink. Mink were inoculated intranasally with a local isolate of Aleutian mink disease virus (AMDV) over 4 years (n = 1742). The animals had been selected for tolerance to AMDV for more than 20 years (TG100) or were from herds free of AMDV (TG0). The progenies of TG100 and TG0, and their crosses with 25, 50 and 75% tolerance ancestry were also used. Blood samples were collected from each mink up to 14 times until 1211 days post-inoculation (dpi) and were tested for viremia by PCR and for anti-AMDV antibodies by counter-immunoelectrophoresis (CIEP). Viremia and CIEP status were not considered when selecting replacements. Low-performing animals were pelted and the presence of antibodies in their blood and antibody titer were measured by CIEP, and viremia and viral DNA in seven organs (n = 936) were tested by PCR. The peak incidences of viremia (66.7%) and seropositivity (93.5%) were at 35 dpi. The incidence of viremia decreased over time while the incidence of seroconversion increased. The least-squares means of the incidence of PCR positive of lymph node (0.743) and spleen (0.656) were significantly greater than those of bone marrow, liver, kidneys, lungs and small intestine (0.194 to 0.342). Differences in tolerant ancestry were significant for every trait measured. Incidences of viremia over time, terminal viremia, seropositivity over time, AMDV DNA in organs and antibody titer were highest in the susceptible groups (TG0 or TG25) and lowest in the tolerant groups (TG100 or TG75). Previous history of selection for tolerance resulted in mink with reduced viral replication and antibody titer. Viremia had a negative effect and antibody production had a positive effect on survival and productivity.
Sections du résumé
BACKGROUND
BACKGROUND
Selecting American mink (Neovison vison) for tolerance to Aleutian mink disease virus (AMDV) has gained popularity in recent years, but data on the outcomes of this activity are scant. The objectives of this study were to determine the long-term changes in viremia, seroconversion and survival in infected mink. Mink were inoculated intranasally with a local isolate of Aleutian mink disease virus (AMDV) over 4 years (n = 1742). The animals had been selected for tolerance to AMDV for more than 20 years (TG100) or were from herds free of AMDV (TG0). The progenies of TG100 and TG0, and their crosses with 25, 50 and 75% tolerance ancestry were also used. Blood samples were collected from each mink up to 14 times until 1211 days post-inoculation (dpi) and were tested for viremia by PCR and for anti-AMDV antibodies by counter-immunoelectrophoresis (CIEP). Viremia and CIEP status were not considered when selecting replacements. Low-performing animals were pelted and the presence of antibodies in their blood and antibody titer were measured by CIEP, and viremia and viral DNA in seven organs (n = 936) were tested by PCR.
RESULTS
RESULTS
The peak incidences of viremia (66.7%) and seropositivity (93.5%) were at 35 dpi. The incidence of viremia decreased over time while the incidence of seroconversion increased. The least-squares means of the incidence of PCR positive of lymph node (0.743) and spleen (0.656) were significantly greater than those of bone marrow, liver, kidneys, lungs and small intestine (0.194 to 0.342). Differences in tolerant ancestry were significant for every trait measured. Incidences of viremia over time, terminal viremia, seropositivity over time, AMDV DNA in organs and antibody titer were highest in the susceptible groups (TG0 or TG25) and lowest in the tolerant groups (TG100 or TG75).
CONCLUSION
CONCLUSIONS
Previous history of selection for tolerance resulted in mink with reduced viral replication and antibody titer. Viremia had a negative effect and antibody production had a positive effect on survival and productivity.
Identifiants
pubmed: 36192746
doi: 10.1186/s12917-022-03462-7
pii: 10.1186/s12917-022-03462-7
pmc: PMC9531452
doi:
Substances chimiques
Antibodies, Viral
0
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
364Informations de copyright
© 2022. The Author(s).
Références
J Clin Microbiol. 1978 Jan;7(1):18-22
pubmed: 203601
Infect Immun. 1983 Sep;41(3):1016-23
pubmed: 6193063
Int Rev Immunol. 2003 Jan-Feb;22(1):65-76
pubmed: 12710504
Virus Res. 2014 May 12;184:14-9
pubmed: 24561116
Prev Vet Med. 2012 Oct 1;106(3-4):332-8
pubmed: 22497690
Am J Vet Res. 1996 Dec;57(12):1706-10
pubmed: 8950422
Intervirology. 1987;27(2):102-11
pubmed: 2444554
Res Vet Sci. 2019 Jun;124:85-92
pubmed: 30856435
Science. 2007 Nov 2;318(5851):812-4
pubmed: 17975068
J Virol. 1988 May;62(5):1495-507
pubmed: 2833604
J Immunol. 1975 Oct;115(4):1034-7
pubmed: 51871
Virol J. 2014 Aug 08;11:141
pubmed: 25103400
Viral Immunol. 2018 Jan/Feb;31(1):69-77
pubmed: 28829241
Prog Med Virol. 1986;33:42-60
pubmed: 3018840
J Infect Dis. 1968 Dec;118(5):510-26
pubmed: 4178323
Acta Pathol Microbiol Immunol Scand C. 1982 Feb;90(1):15-9
pubmed: 7080835
Arch Virol. 2014 May;159(5):1239-47
pubmed: 24212889
Vet Microbiol. 2014 Sep 17;173(1-2):50-8
pubmed: 25139658
Prev Vet Med. 2017 May 1;140:60-66
pubmed: 28460751
J Virol. 1984 Apr;50(1):38-41
pubmed: 6199516
Acta Vet Scand. 2013 Nov 25;55:86
pubmed: 24274663
J Virol Methods. 2014 Apr;199:53-60
pubmed: 24462658
J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):331-4
pubmed: 16316395
Vaccine. 2005 Jan 26;23(10):1225-31
pubmed: 15652664
Can J Microbiol. 2017 Apr;63(4):341-349
pubmed: 28177788
J Virol Methods. 2011 Jan;171(1):81-5
pubmed: 20951744
Acta Pathol Microbiol Immunol Scand Suppl. 1985;287:1-47
pubmed: 3000134
J Clin Microbiol. 1983 Sep;18(3):637-44
pubmed: 6195178
J Gen Virol. 2015 Jun;96(Pt 6):1423-1435
pubmed: 25667324
Prog Med Virol. 1974;18(0):32-47
pubmed: 4214411
Am J Vet Res. 1996 Dec;57(12):1753-8
pubmed: 8950430
Am J Vet Res. 1977 Oct;38(10):1619-24
pubmed: 201189
J Virol. 1985 Sep;55(3):853-6
pubmed: 2991603
Prev Vet Med. 2011 Oct 1;102(1):75-82
pubmed: 21788091
J Anim Breed Genet. 2007 Dec;124(6):323-30
pubmed: 18076469
Front Microbiol. 2015 Oct 12;6:1119
pubmed: 26528267
Appl Environ Microbiol. 1997 Oct;63(10):3741-51
pubmed: 9327537
J Rheumatol. 1974 Mar;1(1):74-92
pubmed: 4376565
Vet Microbiol. 2014 Jan 31;168(2-4):420-7
pubmed: 24389253
J Vet Diagn Invest. 2015 May;27(3):287-94
pubmed: 25862712
Int J Parasitol. 2006 May 1;36(5):521-8
pubmed: 16678182
Infect Agents Dis. 1994 Dec;3(6):279-301
pubmed: 7889316
Vet Microbiol. 2017 May;204:59-63
pubmed: 28532807
Res Vet Sci. 2017 Apr;111:127-134
pubmed: 28249174
Infect Immun. 1975 Jan;11(1):92-4
pubmed: 803925
BMC Vet Res. 2020 Nov 30;16(1):465
pubmed: 33256708
PLoS One. 2015 Mar 30;10(3):e0122194
pubmed: 25822750
Evol Appl. 2012 Jun;5(4):330-40
pubmed: 25568054
Int Arch Allergy Immunol. 2002 Jun;128(2):77-89
pubmed: 12065907
Mol Biotechnol. 2004 Feb;26(2):133-46
pubmed: 14764939
J Vet Sci. 2020 Jul;21(4):e65
pubmed: 32735101
Adv Immunol. 1980;29:261-86
pubmed: 6251709
Acta Vet Scand. 2013 Feb 08;55:10
pubmed: 23394546
Tex Rep Biol Med. 1963;21:37-42
pubmed: 13953842
Immun Inflamm Dis. 2020 Jun;8(2):150-164
pubmed: 32167659
Dtsch Tierarztl Wochenschr. 1990 Feb;97(2):96-9
pubmed: 2155772
Immunol Rev. 2013 Jul;254(1):10-33
pubmed: 23772612
Acta Vet Scand. 1988;29(3-4):315-21
pubmed: 3256231
Sci Rep. 2021 Feb 3;11(1):2944
pubmed: 33536540
Philos Trans R Soc Lond B Biol Sci. 2009 Jan 12;364(1513):37-49
pubmed: 18926971